Detailed description page of ThPDB2

This page displays user query in tabular form.

10735 details
Primary information
ID10735
Therapeutic IDTh1169
Protein NameBeractant
SequenceNA
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting pointNA
Half-life20–30 h.
DescriptionBeractant is a pulmonary surfactant made from natural bovine lung extract.
Indication/DiseaseBeractant is indicated for Respiratory Distress Syndrome (RDS) in premature infants.
PharmacodynamicsEndogenous pulmonary surfactant lowers surface tension on alveolar surfaces during respiration and stabilizes the alveoli against collapse at resting transpulmonary pressures. Deficiency of pulmonary surfactant causes Respiratory Distress Syndrome (RDS) in premature infants. SURVANTA replenishes surfactant and restores surface activity to the lungs of these infants.
Mechanism of ActionIn vitro, SURVANTA reproducibly lowers minimum surface tension to less than 8 dynes/cm as measured by the pulsating bubble surfactometer and Wilhelmy Surface Balance. In situ, SURVANTA restores pulmonary compliance to excised rat lungs artificially made surfactantdeficient. In vivo, single SURVANTA doses improve lung pressure-volume measurements, lung compliance, and oxygenation in premature rabbits and sheep.
ToxicityNA
MetabolismIn surfactant-deficient premature rabbits and lambs, alveolar clearance of radio-labelled lipid components of beractant is rapid. Most of the dose becomes lung-associated within hours of administration, and the lipids enter endogenous surfactant pathways of reutilization and recycling. Limited animal experiments have not found effects of beractant on endogenous surfactant metabolism.
AbsorptionBeractant is administered directly to the target organ, the lungs, where biophysical effects occur at the alveolar surface.
NA
ClearanceNA
CategoriesAlveolar Surface Tension Reduction,Bradycardia-Causing Agents,Complex Mixtures,Pulmonary Surfactants,Respiratory System Agents,Surface-Active Agents,Surfactant Activity
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionBretylium may increase the bradycardic activities of Beractant; Beractant may increase the bradycardic activities of Ceritinib; Esmolol may increase the bradycardic activities of Beractant; Beractant may increase the bradycardic activities of Ivabradine; Beractant may increase the atrioventricular blocking (AV block) activities of Lacosamide; Octreotide may increase the bradycardic activities of Beractant; Ruxolitinib may increase the bradycardic activities of Beractant; Tofacitinib may increase the bradycardic activities of Beractant.
TargetNA
Brand NameSurvanta
CompanyAbbvie Corporation
Brand DescriptionAbbvie Corporation
Prescribed ForSURVANTA is indicated for prevention and treatment (“rescue”) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants. SURVANTA significantly reduces the incidence of RDS, mortality due to RDS and air leak complications.
Chemical NameNA
Formulation25 mg
Physical Appearance Suspension
Route of Administrationintratracheal
Recommended DosageEach dose of SURVANTA is 100 mg of phospholipids/kg birth weight (4 mL/kg).
ContraindicationNA
Side Effectspale skin; slow heartbeat; breathing that stops; urinating less than usual; or blood in the urine; noisy breathing; feeding or bowel problems; or bleeding around the endotracheal tube.
Useful Link 1NA
Useful Link 2NA
RemarksNA